Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function

In January, the FDA approved Eisai and Biogen’s Leqembi (lecanemab) to treat Alzheimer’s disease based on the antibody’s ability to reduce the accumulation of amyloid-beta plaques in the brain. Now, a recently published study has further clarified the drug’s mechanism of action, with potential implications for the future of Alzheimer’s drug development.